All > New York > Dasatinib

Asciminib 40 mg BID single agent group for Chronic Myelogenous Leukemia (CML)

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Chronic Myelogenous Leukemia (CML)+2 MoreECG - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Eligible Conditions
  • Chronic Myelogenous Leukemia (CML)
  • Leukemia
  • Acute Lymphoblastic Leukemia

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
Bosutinib
1
Asciminib
1
Asciminib

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Number of participabts with adverse events (AEs) and serious adverse events (SAEs)
Percentage of participants with clinical benefit as assessed by Investigator

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Bosutinib
2
Asciminib
2
Asciminib

Trial Design

8 Treatment Groups

Asciminib 40 mg BID single agent group
1 of 8
Bosutinib-asciminib switch group
1 of 8
Asciminib in combination with dasatinib group
1 of 8
Asciminib 60 mg QD combined with imatinib group
1 of 8
Asciminib 40 mg QD combined with imatinib group
1 of 8
Asciminib in combination with imatinib group
1 of 8
Asciminib in combination with nilotinib group
1 of 8
Asciminib single agent group
1 of 8

Experimental Treatment

347 Total Participants · 8 Treatment Groups

Primary Treatment: Asciminib 40 mg BID single agent group · No Placebo Group · Phase 4

Asciminib 40 mg BID single agent groupExperimental Group · 2 Interventions: Pregnancy test, Asciminib single agent · Intervention Types: Procedure, Drug
Bosutinib-asciminib switch groupExperimental Group · 3 Interventions: ECG, Pregnancy test, Asciminib single agent · Intervention Types: Procedure, Procedure, Drug
Asciminib in combination with dasatinib group
Drug
Experimental Group · 1 Intervention: Dasatinib · Intervention Types: Drug
Asciminib 60 mg QD combined with imatinib groupExperimental Group · 3 Interventions: Pregnancy test, Asciminib, Imatinib · Intervention Types: Procedure, Drug, Drug
Asciminib 40 mg QD combined with imatinib groupExperimental Group · 3 Interventions: Pregnancy test, Asciminib, Imatinib · Intervention Types: Procedure, Drug, Drug
Asciminib in combination with imatinib groupExperimental Group · 2 Interventions: Asciminib, Imatinib · Intervention Types: Drug, Drug
Asciminib in combination with nilotinib groupExperimental Group · 2 Interventions: Asciminib, Imatinib · Intervention Types: Drug, Drug
Asciminib single agent group
Drug
Experimental Group · 1 Intervention: Asciminib single agent · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ECG
2016
Completed Phase 4
~33530
Pregnancy test
2017
N/A
~530
Asciminib
FDA approved
Imatinib
FDA approved
Dasatinib
2012
Completed Phase 2
~1890

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,717 Previous Clinical Trials
3,524,508 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top